Azidothymidine in the Treatment of AIDS

Pamela jo Harris, Cesar A. Caceres, Barbara Bell, A. Ganser, J. Greher, B. Völkers, S. Staszewski, D. Hoelzer, Douglas D. Richman, Margaret A Fischl, Sandra Nusinoff-Lehrman, David W. Barry

Research output: Contribution to journalLetter

26 Citations (Scopus)

Abstract

To the Editor: Richman et al., in reviewing the experience of the AZT Collaborative Working Group on the toxicity of azidothymidine (zidovudine [Retrovir], or AZT) in the July 23 issue,* reported that 45 percent of patients receiving AZT had some hematologic toxic effects. They also reported that most patients receiving AZT had at least one clinical symptom, such as headache, asthenia, diarrhea, abdominal pain, or fever, but they did not report that any patients had neurologic symptoms. We have recently seen a 43-year-old male patient, positive for antibodies to the human immunodeficiency virus (HIV), who had grand mal epileptic seizures.

Original languageEnglish (US)
Pages (from-to)250-251
Number of pages2
JournalNew England Journal of Medicine
Volume318
Issue number4
DOIs
StatePublished - Jan 28 1988

Fingerprint

Zidovudine
Acquired Immunodeficiency Syndrome
Asthenia
Poisons
Therapeutics
Neurologic Manifestations
Abdominal Pain
Headache
Diarrhea
Epilepsy
Fever
HIV
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Harris, P. J., Caceres, C. A., Bell, B., Ganser, A., Greher, J., Völkers, B., ... Barry, D. W. (1988). Azidothymidine in the Treatment of AIDS. New England Journal of Medicine, 318(4), 250-251. https://doi.org/10.1056/NEJM198801283180412

Azidothymidine in the Treatment of AIDS. / Harris, Pamela jo; Caceres, Cesar A.; Bell, Barbara; Ganser, A.; Greher, J.; Völkers, B.; Staszewski, S.; Hoelzer, D.; Richman, Douglas D.; Fischl, Margaret A; Nusinoff-Lehrman, Sandra; Barry, David W.

In: New England Journal of Medicine, Vol. 318, No. 4, 28.01.1988, p. 250-251.

Research output: Contribution to journalLetter

Harris, PJ, Caceres, CA, Bell, B, Ganser, A, Greher, J, Völkers, B, Staszewski, S, Hoelzer, D, Richman, DD, Fischl, MA, Nusinoff-Lehrman, S & Barry, DW 1988, 'Azidothymidine in the Treatment of AIDS', New England Journal of Medicine, vol. 318, no. 4, pp. 250-251. https://doi.org/10.1056/NEJM198801283180412
Harris PJ, Caceres CA, Bell B, Ganser A, Greher J, Völkers B et al. Azidothymidine in the Treatment of AIDS. New England Journal of Medicine. 1988 Jan 28;318(4):250-251. https://doi.org/10.1056/NEJM198801283180412
Harris, Pamela jo ; Caceres, Cesar A. ; Bell, Barbara ; Ganser, A. ; Greher, J. ; Völkers, B. ; Staszewski, S. ; Hoelzer, D. ; Richman, Douglas D. ; Fischl, Margaret A ; Nusinoff-Lehrman, Sandra ; Barry, David W. / Azidothymidine in the Treatment of AIDS. In: New England Journal of Medicine. 1988 ; Vol. 318, No. 4. pp. 250-251.
@article{63af23666b8a46c78f0da4b7aa77d389,
title = "Azidothymidine in the Treatment of AIDS",
abstract = "To the Editor: Richman et al., in reviewing the experience of the AZT Collaborative Working Group on the toxicity of azidothymidine (zidovudine [Retrovir], or AZT) in the July 23 issue,* reported that 45 percent of patients receiving AZT had some hematologic toxic effects. They also reported that most patients receiving AZT had at least one clinical symptom, such as headache, asthenia, diarrhea, abdominal pain, or fever, but they did not report that any patients had neurologic symptoms. We have recently seen a 43-year-old male patient, positive for antibodies to the human immunodeficiency virus (HIV), who had grand mal epileptic seizures.",
author = "Harris, {Pamela jo} and Caceres, {Cesar A.} and Barbara Bell and A. Ganser and J. Greher and B. V{\"o}lkers and S. Staszewski and D. Hoelzer and Richman, {Douglas D.} and Fischl, {Margaret A} and Sandra Nusinoff-Lehrman and Barry, {David W.}",
year = "1988",
month = "1",
day = "28",
doi = "10.1056/NEJM198801283180412",
language = "English (US)",
volume = "318",
pages = "250--251",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Azidothymidine in the Treatment of AIDS

AU - Harris, Pamela jo

AU - Caceres, Cesar A.

AU - Bell, Barbara

AU - Ganser, A.

AU - Greher, J.

AU - Völkers, B.

AU - Staszewski, S.

AU - Hoelzer, D.

AU - Richman, Douglas D.

AU - Fischl, Margaret A

AU - Nusinoff-Lehrman, Sandra

AU - Barry, David W.

PY - 1988/1/28

Y1 - 1988/1/28

N2 - To the Editor: Richman et al., in reviewing the experience of the AZT Collaborative Working Group on the toxicity of azidothymidine (zidovudine [Retrovir], or AZT) in the July 23 issue,* reported that 45 percent of patients receiving AZT had some hematologic toxic effects. They also reported that most patients receiving AZT had at least one clinical symptom, such as headache, asthenia, diarrhea, abdominal pain, or fever, but they did not report that any patients had neurologic symptoms. We have recently seen a 43-year-old male patient, positive for antibodies to the human immunodeficiency virus (HIV), who had grand mal epileptic seizures.

AB - To the Editor: Richman et al., in reviewing the experience of the AZT Collaborative Working Group on the toxicity of azidothymidine (zidovudine [Retrovir], or AZT) in the July 23 issue,* reported that 45 percent of patients receiving AZT had some hematologic toxic effects. They also reported that most patients receiving AZT had at least one clinical symptom, such as headache, asthenia, diarrhea, abdominal pain, or fever, but they did not report that any patients had neurologic symptoms. We have recently seen a 43-year-old male patient, positive for antibodies to the human immunodeficiency virus (HIV), who had grand mal epileptic seizures.

UR - http://www.scopus.com/inward/record.url?scp=0023832817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023832817&partnerID=8YFLogxK

U2 - 10.1056/NEJM198801283180412

DO - 10.1056/NEJM198801283180412

M3 - Letter

C2 - 3422108

AN - SCOPUS:0023832817

VL - 318

SP - 250

EP - 251

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -